



# **Invasive Group A Streptococcal Infection** in New Zealand, 2016





### Cases and rates by district health board 2016 (421 cases\*)




**PERCENTAGE OF** invasive group A streptococcal cases BY ETHNICITY

**PERCENTAGE OF** 

New Zealand population

**BY ETHNICITY** 



PACIFIC **PEOPLES** have 17x higher risk than European/Other compared to

8x in 2014

**10% (42 deaths)** 30-day case mortality rate

### **Rate increased** with age

1 in 4  $\geq$ 80 years 1 in 2  $\geq$  90 years


> 64 years median age

> > at death

## Cases\* by emm type, 2014–2016

\*emm types with <5 cases in 2016 not shown emm type 2014 2015 2016 89 26 101 82 12 1 41 59 75 4 91 92 81 28 49 58 44 103

# Invasive group A streptococcal infections by year,



104		
11		
53		
71		
15		
42		
65		
70		
76		
111		

Group A Streptococcus strains are categorised by M protein gene (emm) typing.



### **NZ HAS HIGH RATES COMPARED** to other countries and a **DIFFERENT SEASONAL PATTERN**

### **GROUPS MOST AT RISK** Pacific peoples, Māori, very young, elderly and more socio-economically deprived

The group A streptococcal vaccine under development could have prevented up to 48% of cases and 52% of deaths in 2016

Surveillance is important to inform the development of a vaccine



#### www.esr.cri.nz